|
[1]CHEN WQ, ZHENG RS, ZHANG SW, et al.Report of cancer incidence and mortality in China, 2013[J].China cancer, 2017, 26 (1) :1-7. (in Chinese) 陈万青, 郑荣寿, 张思维, 等.2013年中国恶性肿瘤发病和死亡分析[J].中国肿瘤, 2017, 26 (1) :1-7.
|
|
[2]THOMAS MB, CHADHA R, GLOVER K, et al.Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma[J].Cancer, 2007, 110 (5) :1059-1067.
|
|
[3]KASEB AO, GARRETTMAYER E, MORRIS JS, et al.Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome:final results of a phase II trial[J].Oncology, 2012, 82 (2) :67-74.
|
|
[4]HSU CH, KANG YK, YANG TS, et al.Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma:a multicenter phase II study[J].Oncology, 2013, 85 (1) :44-52.
|
|
[5]THOMAS MB, MORRIS JS, CHADHA R, et al.Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma[J].J Clin Oncol, 2009, 27 (6) :843-850.
|
|
[6]PHILIP A, PHILIP MD, HOLEN KD, et al.Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer[J].Cancer, 2012, 118 (9) :2424-2430.
|
|
[7]THOMAS Y, HILDA W, CHAN P, et al.Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease[J].Invest New Drugs, 2012, 30 (6) :2384-2390.
|
|
[8]ZHAO RR, DENG YD, YUAN H.Epidemiological and clinical features of primary cancan:ananalys of 236 patients[J].J Clin Hepatol, 2016, 32 (8) :1538-1542. (in Chinese) 赵荣荣, 邓永东, 袁宏.236例原发性肝癌患者流行病学及临床特点分析[J].临床肝胆病杂志, 2016, 32 (8) :1538-1542.
|
|
[9]ASNACIOS A, FARTOUX L, ROMANO O, et al.Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma:results of a multicenter phase 2 study[J].Cancer, 2008, 112 (12) :2733-2739.
|
|
[10]HANNA K, STEPHEN I, CHARD M, et al.Phase II study of capecitabine, oxaliplatin, and cetuximab for advanced hepatocellular carcinoma[J].Gastrointest Cancer Res, 2011, 4 (3) :78-83.
|
|
[11]KANG YK, YAU T, PARK JW, et al.Randomised phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma[J].Ann Oncol, 2015, 26 (12) :2457-2463.
|
|
[12]CHAN SL, YEO W, MO F, et al.A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma[J].Cancer, 2017, 123 (20) :3977-3985.
|
|
[13]ZHU AX, FINN RS, MULCAHY M, et al.A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer[J].Clin Cancer Res, 2013, 19 (23) :6614-6623.
|
|
[14]ZHU AX, PARK J, RYOO BY, et al.Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH) :a randomized, double-blind, multicenter, phase 3 trial[J].Lancet Oncol, 2015, 16 (7) :859-870.
|
|
[15]ZHU AX, ANCUKIEWICZ M, SUPKO JG, et al.Efficacy, safety, pharmacokinetics and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma:a phase II study[J].Clin Cancer Res, 2013, 19 (6) :1557-1566.
|
|
[16]QIN SK.Apatinib in Chinese patients with advanced hepatocellular carcinoma:a phase II randomized, open-label trial[J].J Clin Oncol, 2014, 32 (15) :17-20.
|
|
[17]LU W, JIN XL, YANG C, et al.Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma:a single-center randomized controlled trial[J].Cancer Biol Ther, 2017, 18 (6) :433-438.
|
|
[18]LLOVET JM, RICCI S, MAZZAFERRO V, et al.SHARP Investigators Study Group.Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med, 2008, 359 (4) :378-390.
|
|
[19]CHENG AL, KANG YK, CHEN Z, et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phase III randomised, double-blind, placebo controlled trial[J].Lancet Oncol, 2009, 10 (1) :25-34.
|
|
[20]JACKSON R, PSARELLI EE, BERHANE S, et al.Impact of viral status on survival in patients receiving sorafenib for advanced hepatocellular cancer:a Meta-analysis of randomized phase III trials[J].J Clin Oncol, 2017, 35 (6) :622-628.
|
|
[21]WANG Y, WANG MQ, DUAN F.Prognostic factor analysis of moderate-advanced hepatocellular carcinoma treated with sorafenib[J].J Intervent Radiol, 2017, 26 (3) :258-262. (in Chinese) 王燕, 王茂强, 段峰.索拉非尼治疗中晚期肝癌预后因素分析[J].介人放射学杂志, 2017, 26 (3) :258-262.
|
|
[22]TAKAHASHI H, NASU K, MINAMI M, et al.Organ atrophy induced by sorafenib and sunitinib-quantitative computed tomography (CT) evaluation of the pancreas, thyroid gland and spleen[J].Pol J Radiol, 2016, 81:557-565.
|
|
[23]XU L, ZHOU DS, ZHAO J, et al.Long-term therapy with sorafenib is associated with pancreatic atrophy[J].J Surg Res, 2015, 199 (2) :314-321.
|
|
[24]PATT Y, ROJAS-HERNANDEZ C, EKRAZAD HM, et al.Phase II trial of sorafenib in combination with capecitabine in patients with hepatocellular carcinoma:INST 08-20[J].Oncologist, 2017, 22 (10) :1158-e116.
|
|
[25]BRUIX J, TAK WY, GABARRINI A, et al.Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma:multicenter, open-label, phase II safety study[J].Eur J Cancer, 2013, 49 (16) :3412-3419.
|
|
[26]BRUIX J, QIN S, MERLE P, et al.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE) :a randomized, double-blind, placebo-controlled, phase 3 trial[J].Lancet, 2017, 389 (10064) :56-66.
|
|
[27]IKEDA M, OKUSAKA T, MITSUNAGA S, et al.Safety and pharmacokinetics of lenvatinib in patients with advanced hepatocellular carcinoma[J].Clin Cancer Res, 2016, 22 (6) :1385-1394.
|
|
[28]IKEDA K, KUDO M, KAWAZOE S, et al.Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma[J].J Gastroenterol, 2017, 52 (4) :512-519.
|
|
[29]ZHUAX, KUDO M, ASSENAT E, et al.Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib:the EVOLVE-1 randomized clinical trial[J].JAMA, 2014, 312 (1) :57-67.
|
|
[30]SANOFF HK, KIM R, LVANOVA A, et al.Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma[J].Invest New Drugs, 2015, 33 (2) :505-509.
|
|
[31]SANTORO A, RIMASSA L, BORBATH I, et al.Tivantinib for second-line treatment of advanced hepatocellular carcinoma:a randomised, lacebo-controlled phase 2 study[J].Lancet Oncol, 2013, 14 (1) :55-63.
|
|
[32]KELLEY RK, VERSLYPE C, COHN AL, et al.Cabozantinib in hepatocellular carcinoma:results of a phase 2 placebo-controlled randomized discontinuation study[J].Ann Oncol, 2017, 28 (3) :528-534.
|
|
[33]SANDRINE JF, ARMANDO S, ROBIN KK, et al.A phase 2 study of a novel transforming growth factor-beta (TGF-β1) receptor I kinase inhibitor, LY2157299 monohydrate (LY) , in patients with advanced hepatocellular carcinoma (HCC) [J].J Clin Oncol, 2014, 32 (Suppl 3) :lba173.
|
|
[34]CAO Y, AGARWAL R, DITURI F, et al.NGS-based transcriptome profiling reveals biomarkers for companion diagnostics of the TGF-βreceptor blocker galunisertib in HCC[J].Cell Death Dis, 2017, 8 (2) :e2634.
|
|
[35]FAN J, ZHOU J, YANG XR.Surgical treatment of hepatocellular carcinoma in the precision medicine era[J].Chin J Dig Surg, 2017, 16 (1) :22-27. (in Chinese) 樊嘉, 周俭, 杨欣荣.精准医学时代的肝癌外科治疗[J].中华消化外科杂志, 2017, 16 (1) :22-27.
|
DownLoad: